© 2001 SAGE Publications
Pharmacoeconomic and Outcomes Analyses in Solid Organ Transplantation
A number of new immunosuppressive agents have been introduced within the past decade. Each of these agents has produced impressive results in Phase III clinical trials, with acute rejection rates declining from the 40% to 50% range to well under 15% to 25% with newer immunosuppressive combinations. However, with the addition of each agent comes an incremental increase in the cost of therapy, resulting in maintenance regimens that vary in price from $1,700 with azathioprine and prednisone to well over $16,000 per year for some of the newer, more potent combinations. Pharmacoeconomic and outcomes analyses can assist practitioners in identifying optimal strategies for patients when selecting among a number of highly effective, but costly, agents. Utilization of these techniques, in combination with the evidence-based medical literature, allows healthcare decision makers to make both scientifically and economically sound decisions. The intent of this article is to provide a review of the current pharmacoeconomics literature for transplantation.